Line Pay, Taiwanese's favorite payment method, launched its IPO on January 26 at the beginning of this year at 348 yuan per share, and the "Initial Public Offering" was listed on the market. The closing price that day soared directly above 1,030.
However, for hot topic stocks, Shangxing counters quickly made huge profits. This excellent historical inheritance was still received. They placed orders early in the morning and then sold them out after listing. It was great to grab them!
Just because everyone sells after the market is listed, and then starts to fall all the way the next day is a good tradition. After all, the leeks that are called into the market when they are half-baked still need to be harvested!
But because Line Pay is a popular product that is commonly used by Taiwanese people, it has not fallen below the expected volume point all the way down. It rebounded as low as 512, and then started to fluctuate back and forth.
After half a year of fluctuations within 100 yuan, yesterday, July 26, I officially submitted a listing application to the Taiwan Stock Exchange. However, due to the impact of the US stock market on the market, it fell for more than a week. As a result, it was unable to rise. The closing price was 526, but I received news earlier. Those who entered the venue had already started running on 7/22.
As a super popular mobile payment concept stock, I can’t say much about whether the later growth will be strong. After all, I am not a poker desk, and I don’t want to affect the operation of the world. I can only say that it depends on whether you have a lot of regularity. used.
Then it applied for listing on the same day, as well as Quanfu Biotechnology (6885-TW), which mainly helped the newly developed "BRM421" new drug, which uses neurotrophic stem cell regeneration peptide (PDSP) to stimulate stem cell differentiation, repair the cornea, and inhibit inflammation. , thereby promoting the healing of dry eyes.
The Regenerative Medicine Act was just passed in its third reading in June. The biotech industry will flourish. People who are interested can pay more attention to it. However, I can only advise that biotech stocks are very weird. If you don’t have a big heart, don’t do it. Try it randomly!
#LinePay # electronic payment # third party #IPO # emerging cabinet # listed # leek # rookie # demon stock # little ghost stock # Lianjia network # mobile payment # Quanfu # biotechnology # regenerative medicine # stem cells # exosomes # stem Eye disease #BRM421 #PDSP # Cornea # Inflammation # Third reading
This website does not have those annoying ads that block the webpage and hinder reading!
If you think the article I wrote is helpful to you, could you please fill in a Questionnaire, allowing me to better understand everyone’s needs and write more high-quality content.
